Navigation Links
StockCall Insight into Eli Lilly, Bristol-Myers Squibb, Astex Pharmaceuticals and Raptor Pharmaceuticals
Date:2/28/2013

LONDON, February 28, 2013 /PRNewswire/ --

Markets responded well to Fed chief Ben Bernanke's remarks about the stimulus policy. On the other hand, there are some worries about the ongoing Sequestration debate as well. However, broader indices remained in the green and The Dow Jones closed 1.26% higher at 14,075.37, the S&P 500 closed 1.27% higher at 1,515.99, and the NASDAQ closed 1.04% higher at 3,162.26. Our research team took a look at major drug makers stocks including companies like Eli Lilly & Co. (NYSE: LLY), Bristol Myers Squibb Co. (NYSE: BMY), Astex Pharmaceuticals Inc. (NASDAQ: ASTX) and Raptor Pharmaceutical Corp. (NASDAQ: RPTP). StockCall has issued technical analysis and charting reports on LLY, BMY, ASTX and RPTP. Download these free reports now at http://www.stockcall.com/todaysopinions

Eli Lilly & Co. is currently in a bullish mode as the stock created a new 52-week high price in its latest trading session. The stock closed the session at $54.80, up 0.68 percent. Eli Lilly traded in the range of $54.26 and $54.99 during the session. Its first support level is at $53.83 and upon breaching this level, the stock may go down to $52.46 level. On the upside, Eli Lilly & Co.'s stock may touch $57.44 level. The stock has traded in the range of $38.56 and $54.99 in the past 52 weeks and it grew by 40 percent during the same time period. On a Year-to-Date basis, the stock is up 11.11 percent. Download the free research on LLY today by registering at http://www.StockCall.com/LLY022813.pdf

Bristol Myers Squibb Co.'s shares also touched a new 52-week high in its latest trading session, ending the day 1.95 percent higher at $37.10. The stock fell to an intra-day low of $36.31, while its intra-day high stood at $37.22. With the upward movement, the stock grew more than 13 percent this year, compared to a gain of 6.3 percent for the S&P 500. The stock has strong support at around $37.03, as it shows a bullish trend. The stock is trading below than its 20-day and 50-day moving averages. Sign up and have access to our free report on BMY at http://www.StockCall.com/BMY022813.pdf

Astex Pharmaceuticals traded in the range of $3.08 and $3.24 in its latest trading session and ended it at $3.19, up 1.92 percent. The stock's 52 weeks range stands at $1.57 and $3.55. Astex Pharma. is up 62.76 percent in the past 12 months, while it gained 9 percent so far this year. The stock is in a bullish mode and may find its first support level at $3.17. It is trading below its 20-day moving average of $3.29 but above its 50-day average price of $3.14. Sign up and read the complimentary report on ASTX at http://www.StockCall.com/ASTX022813.pdf

Shares of Raptor Pharma ended their previous trading session marginally lower at $4.98, down 0.40 percent. The stock lost more than 14 percent this year, in contrast to the broad market. The stock has slipped from $5.03 resistance level. It has support at around $4.87 at the moment. With its downward movement, Raptor is trading below its 20-day moving average price. The stock may touch $5.08 level in the coming trading sessions. The free report on RPTP can be downloaded by signing up now at http://www.StockCall.com/RPTP022813.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at http://www.stockcall.com


'/>"/>
SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. StockCall Research on Boston Scientific and Medtronic: Focus on Paroxysmal Atrial Fibrillation
2. Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents
3. Rittal Corp. Joins the HP ProActive Insight Architecture Alliance
4. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
5. Omnyx Share Their Insight on Agile Software Development for Medical Devices
6. Thomson Reuters Annual Pharmaceutical Factbook Reveals Key Insights into Current Trends
7. GlaxoSmithKline Share Their Insight on Understanding DDI With a View to Better Prediction and Control
8. Pro-Dex Provides Insight Into Fiscal 2013 Operating Plan And Preliminary Results For Fiscal 2012
9. Indegene Introduces TrialPedia 2.0 with Advantage Insights, Making It the Most Comprehensive Clinical Trial Analytics and Decision Support Platform for the Pharma Industry
10. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
11. New Survey Reveals How Patients Choose Their Pharmacy; AccentHealth Garners Consumer Insights from the Waiting Room
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... SILVER SPRING, Md. , March 28, 2017 ... today approved Dupixent (dupilumab) injection to treat adults ... for patients whose eczema is not controlled adequately ... therapies are not advisable. Dupixent can be used ... approval of Dupixent demonstrates our commitment to approving ...
(Date:3/28/2017)... , March 28, 2017  "US Cancer ... on the various indicators and trend analysis related ... drugs in mainstream pharmaceutical market in US. The ... for the growth on cancer generics drugs in ... in saving of billions of dollars for various ...
(Date:3/28/2017)... PHOENIX , March 28, 2017  Today, ... Pharmacy released a new white paper to ... use of latex in healthcare. Specifically, there is substantial confusion ... fact, the FDA has urged manufacturers to drop the term ... labels, because of the challenge to ensure a product is ...
Breaking Medicine Technology:
(Date:3/28/2017)... Calif. (PRWEB) , ... March 28, 2017 , ... ... its leading physicians, Paul Yost, will begin serving as new board chair for ... this month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... corrosive ions found in power plant water and steam. , Chlorides and sulfates ... and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at ...
(Date:3/28/2017)... ... March 28, 2017 , ... A minimally invasive ... “perfect smile.” The National Association of Dental Laboratories (NADL) is informing dentists about ... aware of when utilizing dental laboratories and technicians that create these veneers. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... Association’s Tri-State Camp Conference in Atlantic City March 13-16, was a busy spot ... team of professional staff discussed strategies for preventing outbreaks among camp communities during ...
(Date:3/28/2017)... ... March 28, 2017 , ... Thank you to all ... February 8-10. , This event was exclusive to providers and offered an opportunity ... meeting took place at the Manchester Grand Hyatt where attendees gathered for a lively ...
Breaking Medicine News(10 mins):